These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2960644)

  • 21. Treatment of acyclovir-resistant herpetic ulceration with topical foscarnet and antiviral sensitivity analysis.
    Pechère M; Wunderli W; Trellu-Toutous L; Harms M; Saura JH; Krischer J
    Dermatology; 1998; 197(3):278-80. PubMed ID: 9812037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Foscarnet effective in acyclovir-resistant herpes.
    Am Pharm; 1991 Nov; NS31(11):12. PubMed ID: 1836936
    [No Abstract]   [Full Text] [Related]  

  • 23. Therapeutic effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine, caffeic acid oxidation product, and trisodiumphosphonoformate on cutaneous herpes simplex virus type 1 infection in guinea pigs.
    Helbig B; Sauerbrei A; Klöcking R; Wutzler P; Wicht N; Wiedemann U; Herrmann G
    J Med Virol; 1987 Nov; 23(3):303-9. PubMed ID: 2828526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacies of gel formulations containing foscarnet, alone or combined with sodium lauryl sulfate, against establishment and reactivation of latent herpes simplex virus type 1.
    Piret J; Lamontagne J; Désormeaux A; Bergeron MG
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1030-6. PubMed ID: 11257012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined chemotherapy of cutaneous herpes simplex infection of the guinea pig.
    Burkhardt U; Wigand R
    J Med Virol; 1983; 12(2):137-47. PubMed ID: 6194252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of the treatment protocol upon the in vivo efficacy of cidofovir (HPMPC) and of acyclovir (ACV) formulations in topical treatment of cutaneous HSV-1 infection in hairless mice.
    Afouna MI; Mehta SC; Ghanem AH; Higuchi WI; Kern ER; DeClercq E; El-Shattawy HH
    J Pharm Sci; 1999 May; 88(5):530-4. PubMed ID: 10229644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical course of recurrent genital herpes and treatment with foscarnet cream: results of a Canadian multicenter trial.
    Sacks SL; Portnoy J; Lawee D; Schlech W; Aoki FY; Tyrrell DL; Poisson M; Bright C; Kaluski J
    J Infect Dis; 1987 Feb; 155(2):178-86. PubMed ID: 2949023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiviral effects of phosphonoformate (PFA, foscarnet sodium).
    Oberg B
    Pharmacol Ther; 1989; 40(2):213-85. PubMed ID: 2543994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of phosphonoformate on symptomatic genital herpes simplex virus type 2 infection of guinea pigs.
    Mayo DR; Lucia HL; Hsiung GD
    Intervirology; 1983; 19(1):26-32. PubMed ID: 6298142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Topical phosphonoacetic acid treatment of cutaneous herpes simplex infections in the guinea pig.
    McCarty JR; Jarratt MT
    J Am Acad Dermatol; 1979 Sep; 1(3):244-8. PubMed ID: 512074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased efficacy of ganciclovir in combination with foscarnet against cytomegalovirus and herpes simplex virus type 2 in vitro and in vivo.
    Freitas VR; Fraser-Smith EB; Matthews TR
    Antiviral Res; 1989 Nov; 12(4):205-12. PubMed ID: 2559657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of herpesvirus infections].
    Moeland A; Bruun JN
    Tidsskr Nor Laegeforen; 1991 Sep; 111(22):2751-3. PubMed ID: 1658973
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment of mucocutaneous herpes simplex virus infections unresponsive to acyclovir with topical foscarnet cream in AIDS patients: a phase I/II study.
    Javaly K; Wohlfeiler M; Kalayjian R; Klein T; Bryson Y; Grafford K; Martin-Munley S; Hardy WD
    J Acquir Immune Defic Syndr; 1999 Aug; 21(4):301-6. PubMed ID: 10428108
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sensitivity of cytomegalovirus to intravenous foscarnet treatment.
    Akesson-Johansson A; Lernestedt JO; Ringdén O; Lönnqvist B; Wahren B
    Bone Marrow Transplant; 1986 Dec; 1(2):215-20. PubMed ID: 2844334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group.
    Safrin S; Crumpacker C; Chatis P; Davis R; Hafner R; Rush J; Kessler HA; Landry B; Mills J
    N Engl J Med; 1991 Aug; 325(8):551-5. PubMed ID: 1649971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. "Body burden" of phosphonoformic acid after topical and vaginal administration to rabbits and beagle dogs.
    Hussain AS; Ritschel WA
    Methods Find Exp Clin Pharmacol; 1989 Feb; 11(2):111-4. PubMed ID: 2523506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term follow-up of HIV-infected patients once diagnosed with acyclovir-resistant herpes simplex virus infection.
    Seang S; Boutolleau D; Burrel S; Regnier S; Epelboin L; Voujon D; Valantin MA; Katlama C; Agut H; Caumes E
    Int J STD AIDS; 2014 Aug; 25(9):676-82. PubMed ID: 24535691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-herpes virus combinations in relation to drug resistance.
    Hall MJ
    J Antimicrob Chemother; 1986 Oct; 18 Suppl B():165-76. PubMed ID: 3025155
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mode of action of phosphonoformate as an anti-herpes simplex virus agent.
    Cheng YC; Grill S; Derse D; Chen JY; Caradonna SJ; Connor K
    Biochim Biophys Acta; 1981 Jan; 652(1):90-8. PubMed ID: 6260189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Latent infections of sensory ganglia as influenced by phosphonoformate treatment of herpes simplex virus-induced skin infections in hairless mice.
    Klein RJ; DeStefano E; Brady E; Friedman-Kien AE
    Antimicrob Agents Chemother; 1979 Sep; 16(3):266-70. PubMed ID: 507784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.